Komipharm International Co., Ltd. announced that it expects to receive KRW 10 billion in funding
March 31, 2021
Share
Komipharm International Co., Ltd. (KOSDAQ:A041960) announced a private placement of round 14th unregistered coupon nonguaranteed private convertible bonds for gross proceeds of KRW 10,000,000,000 on March 31, 2021. The transaction will include participation from Fund 1 for KRW 1,000,000,000, Fund 2 for KRW 1,300,000,000, Fund 3 for KRW 2,000,000,000, Fund 4 for KRW 400,000,000, Fund 5 for KRW 600,000,000, Fund 6 for KRW 700,000,000, Fund 7 for KRW 1,500,000,000, Fund 8 for KRW 1,500,000,000 and Fund 9 for KRW 1,000,000,000. The bonds carry no coupon rate and will mature on April 02, 2024. The bonds will be fully convertible into 952,925 shares at a fixed conversion price of KRW 10,494 per share between April 02, 2022 and March 02, 2024. The transaction is expected to close on April 02, 2021. The transaction has been approved by the board of directors of the company. The bonds carry a hold period of one year.
Komipharm International Co Ltd is a Korea-based company principally engaged in the development and manufacture of veterinary vaccines and veterinary pharmaceuticals. The Companyâs main products include veterinary vaccines such as total vaccines of respiratory disease for swine, vaccines of anthrax disease and black leg for cattle, vaccines for infectious bronchitis and Newcastle disease, and canine respiratory infection killed vaccines, and veterinary pharmaceuticals such as antibiotics, nutrients, disinfectants and others, which are used to treat pneumonia, pasteurellosis, enteritis, mastitis, swine erysipelas, septicemia, leptospirosis and bacterial diseases for livestock. The Company also engages in research and development of anticancer drugs and cancer pain-relieving agents. In addition, the Company provides services such as pathological biopsies, serum tests, and bacteria tests.
KOMIPHARM INTERNATIONAL CO., LTD. 
